EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers

Andrew Hantel iD, Eric C Blackstone, Anna C Revette, Jane E Roberts, Alice S Mims, Daniel J DeAngelo, Christopher S Lathan, Gregory A Abel

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Andrew Hantel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Leukemia. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Alliance for Clinical Trials in Oncology Foundation, American Society of Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Demographic enrollment disparities in adult acute leukemia clinical trials limit generalizability and diminish opportunities for minoritized populations to benefit from novel therapies. The distinct natural history and clinical research landscape of acute leukemia, the latter of which is centralized at the National Cancer Institute-designated Comprehensive Cancer Centers (CCCs), pose challenges to eliminating this disparity. Materials and Methods We performed an analysis of 2 qualitative focus group and interview-based studies to characterize barriers and facilitators to representative acute leukemia clinical trial participation. Participants were patients with acute leukemia belonging to under-enrolled demographic groups (female, older adults, Hispanic ethnicity, or non-White race) and clinicians who treat and enroll them in clinical trials at CCCs in Massachusetts and Ohio.

Results

Eight focus groups and 7 individual interviews were performed with 61 participants (34 patients and 27 clinicians). Barriers idiosyncratic to acute leukemia included inpatient and resource-intensive outpatient care, limited time between diagnosis and treatment initiation, low disease prevalence leading to trial centralization, and barriers related to hematopoietic stem cell transplantation. Barriers common across cancer types included restrictive eligibility criteria, complex study logistics, and cost. Potential solutions included local hospital and CCC partnerships and navigation to enhance timely referral and co-management during participation, multi-modal trial education and peer support in the peri-diagnostic period, minimizing unnecessary eligibility criteria, and travel and financial assistance.

Conclusions

Patients and clinicians identified actionable steps to improve trial participation that address the unique challenges for adults with acute leukemia. A multi-pronged and disease-specific approach is needed to achieve representative acute leukemia clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicLeukemiaHumansFemaleNational Cancer Institute (U.S.)MaleMiddle AgedAdultUnited StatesCancer Care FacilitiesAgedFocus GroupsPatient Selection

Stichwörter der Autor:innen

acute leukemiaclinical trial enrollmenthealth disparitieshealth equity

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
  • Harvard Medical School, Boston, MA 02115, United States.
  • HMS Center for Bioethics, Boston, MA 02115, United States.
  • The Ohio State University, Columbus, OH 43210, United States.

ORCID-Profile: Andrew Hantel

Förderung

  • NCI NIH HHS
  • Alliance for Clinical Trials in Oncology Foundation
  • American Society of Clinical Oncology
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Hantel, A., Blackstone, E. C., Revette, A. C., Roberts, J. E., Mims, A. S., DeAngelo, D. J., Lathan, C. S., & Abel, G. A. (2025). Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers. The Oncologist. https://doi.org/10.1093/oncolo/oyaf241

Vancouver

Hantel A, Blackstone EC, Revette AC, Roberts JE, Mims AS, DeAngelo DJ, et al. Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers. The Oncologist. 2025. doi:10.1093/oncolo/oyaf241

BibTeX
@article{Hantel2025,
  author = {Hantel, Andrew and Blackstone, Eric C and Revette, Anna C and Roberts, Jane E and Mims, Alice S and DeAngelo, Daniel J and Lathan, Christopher S and Abel, Gregory A},
  title = {Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf241}
}
Kostenlos starten →